01—Abstract
Summary
Summary of the 20-F filed May 21, 2019. Cited figures are marked; the original filing is the authoritative source.
James Hardie Industries plc's 2019 Annual Report on Form 20-F (fiscal year ended 31 March 2019) reports net sales of US$2,506.6 milliona, up from US$2,054.5 million, with net income of US$228.8 million versus US$146.1 million in fiscal 2018.
The increase was driven largely by the Fermacell acquisition, completed on 3 April 2018 for a purchase price of €516.4 million, which added the Europe Building Products segment (net sales of US$368.3 millionb). Net income was helped by a favorable movement in asbestos adjustments, which were a US$22.0 million expense versus US$156.4 million in fiscal 2018, partly offset by higher SG&A (US$403.6 million, up 30%) and a product line discontinuation charge of US$29.5 million tied to the exit of the fiberglass windows business and the MCT product line. The balance sheet expanded significantly, with total assets of US$4,032.6 million versus US$2,351.0 million and total shareholders' equity of US$974.4 million, compared with a deficit of US$(221.5) million a year earlier.
Net debt rose to US$1,301.6 millionc from US$602.8 million, reflecting the Fermacell financing. Net cash from operating activities was US$287.6 million, and cash used in investing activities was US$848.0 million, including the US$558.7 million acquisition. The company expects continued modest US housing market growth into fiscal 2020 and expects its Europe Building Products segment to deliver year-on-year net sales and operating income margin growth.
The filing's key ongoing risk remains the asbestos liability under the AFFA, recorded at US$1,089.6 milliond gross and US$608.4 million net of tax, with annual payments to AICF of up to 35% of free cash flow. A payment of approximately US$100.9 million is anticipated on 1 July 2019. Other notable items include one customer accounting for greater than 10% of net sales each year, and the company's Irish domicile and US-Ireland treaty dependence.
02—Key points
Key Highlights
- Net sales rose 22% to US$2,506.6 million, driven by the Fermacell acquisition and higher North America and Asia Pacific Fiber Cement sales.
- Net income increased to US$228.8 million from US$146.1 million, primarily due to a favorable movement in asbestos adjustments (US$22.0 million expense vs. US$156.4 million in FY18).
- Gross margin was 33.2%, down 2.3 percentage points, with higher pulp and freight costs cited as key drivers in North America.
- SG&A increased 30% to US$403.6 million, reflecting Fermacell transaction and integration costs and higher labor and discretionary spend.
- Net debt rose to US$1,301.6 million from US$602.8 million, following financing of the Fermacell acquisition through senior notes and a term loan.
- Gross AICF asbestos liability was US$1,089.6 million; the company expects a payment of approximately US$100.9 million to AICF on 1 July 2019.
- Total shareholders' equity turned positive at US$974.4 million, up from a deficit of US$(221.5) million, after a US$1,160.3 million cumulative adjustment from adopting ASU 2016-16.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, James Hardie Industries kept $0.09.
- Revenue$2.51B100.0%
- Cost of revenue−$1.68B66.8%
- Gross profit$831.0M33.2%
- Operating costs−$479.4M19.1%
- Operating income$351.6M14.0%
- Interest, other & tax−$122.8M4.9%
- Net income$228.8M9.1%
Where FY2019 revenue went
$2.51B- Cost of revenue: $1.68B, 67% of revenue
- SG&A: $403.6M, 16% of revenue
- Net income: $228.8M, 9.1% of revenue
- R&D: $37.9M, 1.5% of revenue
- Other operating costs: $37.9M, 1.5% of revenue
- Interest, other & tax: $122.8M, 4.9% of revenue
Kept 9.1% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2019filed May 21, 2019Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $2.51B$2.05B | +22.0% |
| Cost of Revenue | $1.68B$1.32B | +26.5% |
| Gross Profit | $831.00M$730.20M | +13.8% |
| R&D Expenses | $37.90M$33.30M | +13.8% |
| SG&A Expenses | $403.60M$311.30M | +29.6% |
| Operating Income | $351.60M$229.20M | +53.4% |
| Interest Expense | $54.20M$32.90M | +64.7% |
| Net Income | $228.80M$146.10M | +56.6% |
| EPS (Basic) | $0.52$0.33 | +57.6% |
| EPS (Diluted) | $0.52$0.33 | +57.6% |
| Shares Outstanding (Basic) | 441.90M441.20M | +0.2% |
| Shares Outstanding (Diluted) | 443.00M442.30M | +0.2% |
05—Questions
Frequently Asked Questions
What drove the increase in net sales in fiscal 2019?
Net sales increased to US$2,506.6 million from US$2,054.5 million. The filing states that the increase was favorably impacted by the acquisition of Fermacell in Europe, which contributed US$368.3 million in Europe Building Products segment net sales, along with higher net sales in North America Fiber Cement and Asia Pacific Fiber Cement.
How did asbestos adjustments affect results?
Asbestos adjustments were an expense of US$22.0 million in fiscal 2019, compared with US$156.4 million in fiscal 2018. The filing attributes the expense mainly to an unfavorable actuarial adjustment of US$72.7 million, partly offset by a US$49.5 million favorable foreign exchange effect on asbestos net liabilities.
What is the company's outlook?
The company expects modest market growth and a more prolonged recovery of the US housing market to continue into fiscal 2020, with growth lower than in fiscal 2019. It anticipates that addressable underlying market in Australia will decrease, and expects the Europe Building Products segment to achieve year-on-year net sales and operating income margin growth.
What are the main risks related to the asbestos liability?
The company records a gross asbestos liability of US$1,089.6 million, with a net unfunded AFFA liability of US$608.4 million after tax. Payments to AICF are linked to free cash flow, with annual payments of up to 35% of free cash flow, and future actuarial estimates or claim trends could require the company to increase its liability or extend payment periods.
06—Continue